Rafferty Domnick Cunningham & Yaffa Spotlights Critical Patient Safety Concerns Following FDA GLP-1 Warning
Katherine A. Kiziah, a partner at Rafferty Domnick Cunningham & Yaffa, was featured in a GlobeNewswire release addressing critical patient safety concerns following a new U.S. Food and Drug Administration (FDA) warning involving GLP-1 medications. The coverage highlights the FDA’s decision to require updated safety labels for medications such as Ozempic, Wegovy, Mounjaro, and Zepbound due to a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can cause permanent vision loss.
The FDA’s updated labeling requirements follow an analysis of clinical trials identifying a potential association between GLP-1 medications and NAION. The agency is encouraging patients to seek immediate medical attention for sudden vision changes and consult their healthcare providers about treatment decisions.
In the coverage, Kiziah emphasizes the importance of transparency, ongoing medication safety monitoring, and ensuring patients receive timely information about emerging health risks. She also addresses pharmaceutical manufacturers’ responsibility to evaluate new safety findings and communicate significant developments that could affect patients.
The FDA’s action highlights the importance of continued oversight as GLP-1 medications become more widely prescribed for diabetes and weight management.
Rafferty Domnick Cunningham & Yaffa continues its work representing individuals and families affected by pharmaceutical products, medical devices, and other forms of alleged corporate negligence.
